Jun 15th 2012 - Edison Investment Research today published a report on BioInvent entitled "Survival Of The Fittest". In summary, the report says:
The market has taken an irrational view of the failure of un-partnered TB-402 and the return of rights to TB-403. TB-402 accounted for only 4% of Edison’s future revenue estimate, while TB-403 contributed no value. The events focus BioInvent on to its two most valuable assets: BI-204 for atherosclerosis and BI-505 for multiple myeloma and possibly other cancers. Data on both products are due in Q3 and good indicative results on BI-204 could lead to a milestone, sale of ex-North America rights and Genentech/Roche making significant further investments.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »